Remove 2025 Remove Communication Remove Labelling
article thumbnail

Pharmaceutical Marketing in 2025: Trends, Tech, and Targeting That Matter Most

Pharma Marketing Network

Introduction Pharmaceutical marketing is entering a new era in 2025, driven by rapid advancements in technology, evolving patient expectations, and tighter compliance demands. Similarly, patients benefit from communications that resonate with their condition, treatment stage, and lifestyle.

HIPAA 52
article thumbnail

Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight

The FDA Law Blog

The first phaseout milestone is less than a year away; by May 6, 2025 most laboratories will need to demonstrate compliance with Medical Device Reporting (21 C.F.R. § 11] In the context of an LDT, it is unclear what FDA will include within the scope of “labeling” and what types of communications will be considered “claims.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eco-directed sustainable prescribing practices: awareness and implementation

Hospital Pharmacy Europe

They suggested that pharmacy-specific interventions should include targeted messaging and informative displays at the point of care, clearer labelling on medications to highlight their environmental impact and better access to pharmacy return schemes for unwanted medicines. 2025 Jan 20;15(1):e088066. doi: 10.1136/bmjopen-2024-088066.

article thumbnail

New chronic asthma guideline: pharmacological management updates and implications

Hospital Pharmacy Europe

Timely follow-up after hospital attendance and communication at transfers of care is therefore imperative Identifying patients through targeted searching of primary care databases is expected to be a way to review prescribing and revisit diagnosis. Accessed February 2025]. Accessed February 2025]. Accessed February 2025].

article thumbnail

FDA Hosts Webinar for Stage 1 Requirements under LDT Final Rule

The FDA Law Blog

Corrections and Removals Under 21 CFR Part 806, manufacturers generally need to communicate corrections and removals (i.e., Stage 1 is scheduled to take effect on May 6, 2025. FDA plans to hold its next webinar on September 24, 2024, which will cover the labeling requirements that go into effect in Stage 2.

FDA 64
article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

Wireless medical devices use wireless radio frequency communication such as wifi, Bluetooth, and cellular/mobile phone technology. Is the software performing an action on data different from storage, archival, communication, or simple search? Global Strategy on Digital Health 2020-2025.” Wireless medical devices.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

Wireless medical devices use wireless radio frequency communication such as wifi, Bluetooth, and cellular/mobile phone technology. Is the software performing an action on data different from storage, archival, communication, or simple search? Global Strategy on Digital Health 2020-2025.” Wireless medical devices.